Objectives Screening of monoclonal B-cell lymphocytosis (MBL) has improved the early detection of B-cell lymphoproliferative disorders (B-LPDs). This study was designed to find the most cost-effective ...

GSK plc (NYSE:GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA ...

The US Food and Drug Administration (FDA) has approved the belimumab 200 mg/mL autoinjector for children aged 5 years of older with active lupus nephritis (LN) who are receiving standard therapy.

Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, ...

The US FDA has approved GSK's 200 mg/ml autoinjector of Benlysta for individuals aged five years and above with active lupus ...

GSK’s approval expands belimumab treatment options, offering a first-of-its-kind subcutaneous option that can be administered ...

Systemic lupus erythematosus (SLE) is characterised by numerous abnormalities in B lineage cells, including increased CD27++ plasmablasts/plasma cells, atypical CD27-IgD- B cells with increased CD95, ...

He, L., Zhou, Y., Wang, Q.T., Liu, J. and Ma, J.P. (2025) Two Pathological Patterns in Different Stages of the Same Disease. Journal of Biosciences and Medicines, 13, 189-195. doi: ...

Chronic inflammation in response to lipoprotein accumulation in the arterial wall is central in the development of atherosclerosis. Both innate and adaptive immunity are involved in this process.

Chronic inflammation in response to lipoprotein accumulation in the arterial wall is central in the development of atherosclerosis. Both innate and adaptive immunity are involved in this process.

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...